Target intelligence / Profile preview

Presynaptic nicotinic acetylcholine receptor (pre-nAChR)

Target
pre-nAChR
Molecular classification
Ion channel, Ligand-gated ion channel, Nicotinic acetylcholine receptor, Cys-loop receptor
01

Overview

Presynaptic nicotinic acetylcholine receptors (pre-nAChRs) are ligand-gated ion channels located on the motor nerve terminals at the neuromuscular junction (NMJ). Unlike their postsynaptic counterparts which mediate muscle contraction, these receptors—primarily composed of alpha3beta2 or alpha7 subunits—function as part of a positive feedback loop that sustains acetylcholine (ACh) release during high-frequency nerve stimulation (Fagerlund & Eriksson, 2009). When ACh is released into the synaptic cleft, it binds to these presynaptic receptors, triggering the mobilization of ACh vesicles from the reserve pool to the readily releasable pool (Bowman, 2006). This mechanism is essential for maintaining the safety margin of neuromuscular transmission and preventing neurotransmitter depletion during rapid activity. In clinical anesthesia, non-depolarizing neuromuscular blocking agents (NMBAs) antagonize these receptors, which results in the characteristic 'fade' observed during peripheral nerve stimulation (StatPearls, 2023). Dysfunction or pharmacological blockade of these receptors is a key factor in the pathophysiology of neuromuscular weakness and the monitoring of recovery from anesthesia.

Other names
Presynaptic nAChRNeuronal-type nicotinic receptor at the motor nerve terminalAutoreceptor nicotinic acetylcholine receptorAlpha3beta2 nicotinic receptorAlpha7 nicotinic receptor
02

Mechanism of action

Antagonism of presynaptic nicotinic receptors inhibits the positive feedback mechanism for acetylcholine mobilization, leading to a progressive decrease in neurotransmitter release during repetitive nerve stimulation, clinically manifested as neuromuscular fade.

03

Biological functions

Positive feedback of acetylcholine releaseNeurotransmitter mobilizationNeuromuscular transmission modulationRegulation of synaptic plasticity
04

Disease associations

Myasthenia gravisLambert-Eaton myasthenic syndromeCritical illness polyneuromyopathyCongenital myasthenic syndrome
05

Safety considerations

Residual neuromuscular blockadeRespiratory insufficiencyMuscle fatiguePotentiation by certain antibiotics (e.g., aminoglycosides)
06

Interacting drugs

Rocuronium

6 more in the full profile.

07

Biomarkers

Train-of-four (TOF) ratioTetanic fadePost-tetanic count

Beyond the preview

Go deeper on Presynaptic nicotinic acetylcholine receptor (pre-nAChR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Presynaptic nicotinic acetylcholine receptor (pre-nAChR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call